To ask the Secretary of State for Health and Social Care, whether contingency planning and expenditure by the Medicines and Healthcare products Regulatory Agency (MHRA) on any systems or processes, including software is being incurred on systems or processes which will be redundant in the event that an agreement is reached that includes continued full co-operation, based on regulatory alignment, with the European Medicines Agency after the UK leaves the EU.

The Medicines and Healthcare products Regulatory Agency (MHRA) has undertaken contingency planning in the event the United Kingdom leaves the European Union with no deal. MHRA currently interacts with 40 systems and processes. The total estimated cost to replace them is expected to be £9.3 million on completion.